For the quarter ended December 2025, Aquestive Therapeutics (AQST) reported revenue of $13.02 million, up 9.7% over the same period last year. EPS came in at -$0.26, compared to -$0.19 in the year-ago quarter.
The reported revenue represents a surprise of -2.64% over the Zacks Consensus Estimate of $13.37 million. With the consensus EPS estimate being -$0.13, the EPS surprise was -100%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- License and royalty revenue: $0.85 million compared to the $1.82 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.
- Revenues- Co-development and research fees: $0.18 million versus the two-analyst average estimate of $0.55 million. The reported number represents a year-over-year change of -33.9%.
- Revenues- Manufacture and supply revenue: $11.98 million versus the two-analyst average estimate of $11.4 million. The reported number represents a year-over-year change of +12.4%.
View all Key Company Metrics for Aquestive Therapeutics here>>>
Shares of Aquestive Therapeutics have returned +0.5% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aquestive Therapeutics, Inc. (AQST): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
